Besides the value of pS727-STAT3 as a prognostic factor of overall survival in ccRCC patients, our results also indicate that it may be useful as a novel biomarker to select patients who are candidates for adjuvant therapy. This evidence concerns the gene STAT3 and nonpapillary renal cell carcinoma.